An open trial of plant-source derived phosphatydilserine for treatment of age-related cognitive decline.
We assessed whether the efficacy of plant-source derived phosphatydilserine (one of the phospholipids which play an important functional role in membrane-related processes in the brain) for treatment of age related cognitive decline is consistent with previous (placebo controlled) positive findings with bovine derivative of PS (BC-PS). Eighteen healthy elderly volunteers meeting Age Associated Memory Impairment inclusion and exclusion criteria were treated for 12 weeks with plant-source derived phosphatydilserine (PS) (100 mg x 3/day p.o.) and evaluated at base line, after 6 weeks of treatment and at the end of the trial. Fifteen concluded the study. All but two outcome measures elicited a significant drug over time effect. Post-hoc paired t-tests showed that the significant effect was attributable to an improvement from base line to week 6 and that effect was maintained at week 12. These results are encouraging. However, they await double-blind controlled verification in a large sample before suggesting that this may be a viable approach to the treatment of age-related cognitive decline, without exposing the patients to possible hazards involved in the treatment with bovine derivative of PS (BC-PS).
Schreiber
S
S
Department of Psychiatry C, Chaim Sheba Medical Center, and Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel. shaulsch@post.tau.ac.il
Kampf-Sherf
O
O
Gorfine
M
M
Kelly
D
D
Oppenheim
Y
Y
Lerer
B
B
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D009483:Neuropsychological Tests; D010718:Phosphatidylserines / Q000627:therapeutic use*; D010936:Plant Extracts / Q000627:therapeutic use*
D010718:Phosphatidylserines; D010936:Plant Extracts